Abpro Holdings, Inc.

Abpro Holdings, Inc. is a clinical-stage biotechnology company that develops multispecific antibody therapeutics, primarily focusing on immuno-oncology for solid tumors and ocular vascular diseases such as retinal neovascular and vascular leakage disorders. The company's technology platforms, DiversImmune and MultiMab, are designed to create multispecific antibodies that can engage multiple targets simultaneously, aiming to improve potency, selectivity, and therapeutic window. Headquartered in Woburn, Massachusetts, United States, Abpro Holdings, Inc. was incorporated in 2004. Its lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 for HER2+ solid tumors like breast and gastric cancers, and ABP-201, a TetraBi antibody format designed to inhibit VEGF and ANG-2 simultaneously for vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. Other candidates in development are ABP-110 for hepatocellular carcinoma and ABP-150 for gastric cancers. Abpro Holdings, Inc. operates with in-house research and development, supported by strategic partnerships with companies like Celltrion Inc. and Abpro Bio International, Inc., and relies on collaborations for development and manufacturing scale-up. The company became publicly traded through a business combination and is listed on NASDAQ under the ticker ABP. Sources: [1] https://www.bitget.com/wiki/abp-stock [2] https://au.investing.com/equities/atlantic-coastal-acquisition-ii-company-profile [3] https://crueltyfreeinvesting.org/companies/abpro-holdings-inc/